Toxoplasmosis Treatment Drugs Market, by Indication, by Route of Administration, by Drug Class, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Toxoplasma gondii is an intracellular parasite, which can cause lifelong infection. The infection lives in the brain and sometimes in the eyes in about 30 percent of all humans. It is caused due to drinking contaminated water, consuming infected undercooked meat, or exposure to these parasites in soil. These parasites usually occur in unborn babies, newborns, children and adults. While most healthy adults who are exposed to the parasite never experience any serious symptoms, but dormant, unrecognized, smoldering infections can emerge years later in immune-compromised patients.

Market Dynamics

Increasing incidence of cancer is expected to increase the chemotherapy procedures leading to the toxoplasmosis infection, and thereby driving the market growth over the forecast period. According to the World Cancer Research Fund International's report, in 2018 lung cancer was at first position in the total number of cancer cases worldwide, accounting for 2,093,876 new cases worldwide in 2018. According to the same source, breast cancer accounted second position and the new cases reported was 2,088,849 globally in 2018.

Rising number of chemotherapy procedures can lead to increase in the number of toxoplasmosis infection thereby assisting the market growth. According to the Division of Cancer Prevention and Control, Centers for Disease Control and Prevention, in November 2020, stated that nearly 650,000 cancer patients in the U.S. receive chemotherapy in an outpatient oncology clinic annually.

Increasing prevalence of Acquired Immunodeficiency Syndrome (AIDS) caused due to HIV may lead to low immunity and toxoplasmosis infection and, thereby, drive the growth of toxoplasmosis treatment drugs market during the forecast period. For instance, according to the UNAIDS, 2021, around 1.7 million new cases of HIV infection was registered globally in 2018.

Key features of the study:

• This report provides in-depth analysis of the global toxoplasmosis treatment drugs market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2028), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global toxoplasmosis treatment drugs market based on the following parameters - company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
• Key companies covered as a part of this study are Vyera Pharmaceuticals LLC, Taj Accura Pharmaceuticals Ltd, Mangalam Drugs and Organics Ltd., Cerovene Healthcare PVT LTD, Greenstone LLC, Amneal Pharmaceuticals, Inc., Turing Pharmaceuticals, F. Hoffmann-La Roche AG, Teva Pharmaceutical Industries Ltd, and Baxter International Inc.
• Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future drug launches, drug class up-gradation, market expansion, and marketing tactics
• The global toxoplasmosis treatment drugs market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global toxoplasmosis treatment drugs market.

Detailed Segmentation:

• Global Toxoplasmosis Treatment Drugs Market, By Indication:
  • Chronic Toxoplasmosis Infection
  • Acute Toxoplasmosis Infection
• Global Toxoplasmosis Treatment Drugs Market, By Route of Administration:
  • Parenteral
  • Oral
• Global Toxoplasmosis Treatment Drugs Market, By Drug Class:
  • Pyrimethamine
  • Spiramycin
  • Leucovorin
  • Sulfadiazine
  • Folic Acid
  • Other
• Global Toxoplasmosis Treatment Drugs Market, By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Global Toxoplasmosis Treatment Drugs Market, By Region:
  • North America
    • By Indication:
    • Chronic Toxoplasmosis Infection
    • Acute Toxoplasmosis Infection
    • By Route of Administration
    • Parenteral
    • Oral
    • By Drug Class
    • Pyrimethamine
    • Spiramycin
    • Leucovorin
    • Sulfadiazine
    • Folic Acid
    • Other
    • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • By Country:
    • U.S.
    • Canada
  • Latin America
    • By Indication:
    • Chronic Toxoplasmosis Infection
    • Acute Toxoplasmosis Infection
    • By Route of Administration
    • Parenteral
    • Oral
    • By Drug Class
    • Pyrimethamine
    • Spiramycin
    • Leucovorin
    • Sulfadiazine
    • Folic Acid
    • Other
    • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • By Country:
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • By Indication:
    • Chronic Toxoplasmosis Infection
    • Acute Toxoplasmosis Infection
    • By Route of Administration
    • Parenteral
    • Oral
    • By Drug Class
    • Pyrimethamine
    • Spiramycin
    • Leucovorin
    • Sulfadiazine
    • Folic Acid
    • Other
    • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • By Country:
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • By Indication:
    • Chronic Toxoplasmosis Infection
    • Acute Toxoplasmosis Infection
    • By Route of Administration
    • Parenteral
    • Oral
    • By Drug Class
    • Pyrimethamine
    • Spiramycin
    • Leucovorin
    • Sulfadiazine
    • Folic Acid
    • Other
    • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • By Country:
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • By Indication:
    • Chronic Toxoplasmosis Infection
    • Acute Toxoplasmosis Infection
    • By Route of Administration
    • Parenteral
    • Oral
    • By Drug Class
    • Pyrimethamine
    • Spiramycin
    • Leucovorin
    • Sulfadiazine
    • Folic Acid
    • Other
    • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • By Country:
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • By Indication:
    • Chronic Toxoplasmosis Infection
    • Acute Toxoplasmosis Infection
    • By Route of Administration
    • Parenteral
    • Oral
    • By Drug Class
    • Pyrimethamine
    • Spiramycin
    • Leucovorin
    • Sulfadiazine
    • Folic Acid
    • Other
    • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • By Country/Region:
    • South Africa
    • Central Africa
    • North Africa
• Company Profiles
  • Vyera Pharmaceuticals LLC*
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Key Highlights
    • Market Strategies
  • Taj Accura Pharmaceuticals Ltd
  • Mangalam Drugs and Organics Ltd.
  • Cerovene Healthcare PVT LTD
  • Greenstone LLC
  • Amneal Pharmaceuticals, Inc.
  • Turing Pharmaceuticals
  • F. Hoffmann-La Roche AG
  • Teva Pharmaceutical Industries Ltd
  • Baxter International Inc.

"*" marked represents similar segmentation in other categories in the respective section.